Dr. Kristopher P. Wentzel, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
1200 N State St, Ct-a7d
Los Angeles, CA 90033
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Miami, Lm Miller School of Medicine (2012)
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 346
Licensed in California since 2014, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Medical school: University of Miami, Lm Miller School of Medicine
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license A128813 (first issued 2014; current) - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cedars-Sinai Medical Center Los Angeles, CA
- Saint John's Health Center Santa Monica, CA
- Cedar-Sinai Marina Del Rey Hospital Marina Del Rey, CA
Medical groups
- Cedars-Sinai Medical Care Foundation (1,692 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 346
- Services billed
- 120,881
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 21,750 | 15 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 10,250 | 15 |
| Injection, denosumab, 1 mg | 5,640 | 32 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,341 | 245 |
| Blood test, comprehensive group of blood chemicals | 1,215 | 247 |
| Lactate dehydrogenase (enzyme) level | 1,119 | 230 |
| Phosphate level | 1,115 | 229 |
| Uric acid level, blood | 1,113 | 228 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,077 | 237 |
| Insertion of needle into vein for collection of blood sample | 1,039 | 210 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Abiraterone Acetate | 53 |
| Prednisone Other prescribers in Los Angeles, CA | 48 |
| Eliquis (apixaban) Other prescribers in Los Angeles, CA | 38 |
| Hydroxyurea Other prescribers in Los Angeles, CA | 36 |
| Warfarin Sodium Other prescribers in Los Angeles, CA | 34 |
| Xarelto (rivaroxaban) Other prescribers in Los Angeles, CA | 26 |
| Lenalidomide | 25 |
| Enoxaparin Sodium Other prescribers in Los Angeles, CA | 23 |
| Gabapentin Other prescribers in Los Angeles, CA | 16 |
| Xtandi (enzalutamide) | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $20.39 in total to this clinician.
| Array Biopharma Inc | $20.39 |
|---|
| Food and Beverage | $20.39 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $875,889 in research payments for these studies, mostly to the institutions running them.
- An open-label phase 1,2A study of GV20-0251 monotherapy and GV20-0251 in combination with pembrolizumab in participants with advanced and,or refractory solid tumor malignancies
Merck Sharp & Dohme LLC - A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
Exelixis Inc. - A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies
Incyte Corporation - A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
Exelixis Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.